ArticleMolecular cancer research : MCR2012
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.
Article in Molecular cancer research : MCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Endoscopic Hallmarks of Sessile Serrated Lesions: A Systematic Review of an Evolving Concept.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Elucidating the molecular determinants in the process of gastrin C-terminal pentapeptide amide end activating cholecystokinin 2 receptor by Gaussian accelerated molecular dynamics simulations.Frontiers in pharmacology · 2022Article
- The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.Frontiers in endocrinology · 2020Review
- Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells.Hormones & cancer · 2018Article
- Expression of cholecystokinin receptors in colon cancer and the clinical correlation in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort.Pancreas · 2016Article
- Neural mechanism of gastric motility regulation by electroacupuncture at RN12 and BL21: A paraventricular hypothalamic nucleus-dorsal vagal complex-vagus nerve-gastric channel pathway.World journal of gastroenterology · 2015Article
- Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues.PloS one · 2014Article
- A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA.PloS one · 2014Article
- The duration of gastrin treatment affects global gene expression and molecular responses involved in ER stress and anti-apoptosis.BMC genomics · 2013Article
- A Speculative Role for Stromal Gastrin Signaling in Development and Dissemination of Pancreatic Ductal Adenocarcinoma.Pancreatic disorders & therapy · 2013Article
- NR4A2 is regulated by gastrin and influences cellular responses of gastric adenocarcinoma cells.PloS one · 2013Article
- Gastrin receptor pharmacology.Current gastroenterology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
The roles of cholecystokinin 2 receptor (CCK2R) in numerous physiologic processes in the gastrointestinal tract and central nervous system are well documented. There has been some evidence that CCK2R alterations play a role in cancers, but the functional significance of these alterations for tumorigenesis is unknown. We have identified six mutations in CCK2R among a panel of 140 colorectal cancers and 44 gastric cancers. We show that these mutations increase receptor activity, activate multiple downstream signaling pathways, increase cell migration, and promote angiogenesis. Our findings suggest that somatic mutations in CCK2R may promote tumorigenesis through deregulated receptor activity and highlight the importance of evaluating CCK2R inhibitors to block both the normal and mutant forms of the receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.